$BTCY
BIOTRICITY INC. Stock $btcy

$btcy Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224033159 Filed on August 19, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$3.267M	$3.202M	$3.021M
YoY Change	12.99%	5.99%	46.92%
Cost Of Revenue	$807.7K	$838.6K	$1.104M
YoY Change	-9.46%	-24.05%	32.87%
Gross Profit	$2.459M	$2.363M	$1.917M
YoY Change	23.0%	23.29%	56.45%
Gross Profit Margin	75.28%	73.81%	63.45%
Selling, General & Admin	$2.249M	$2.966M	$3.520M
YoY Change	-35.51%	-15.74%	-27.41%
% of Gross Profit	91.45%	125.51%	183.66%
Research & Development	$518.0K	$513.9K	$713.0K
YoY Change	-25.75%	-27.92%	-13.18%
% of Gross Profit	21.06%	21.75%	37.2%
Depreciation & Amortization		$1.488K	$1.489K
YoY Change		-0.07%	0.0%
% of Gross Profit		0.06%	0.08%
Operating Expenses	$2.767M	$3.480M	$4.233M
YoY Change	-33.89%	-17.79%	-25.76%
Operating Profit	-$307.7K	-$1.117M	-$2.316M
YoY Change	-85.92%	-51.79%	-48.26%
Interest Expense	$752.1K	$768.7K	$660.5K
YoY Change	-0.16%	16.38%	-910.64%
% of Operating Profit
Other Income/Expense, Net	$36.31K	-$229.8K	$13.44K
YoY Change	-125.33%	-1810.46%
Pretax Income	-$1.562M	-$3.695M	-$3.413M
YoY Change	-57.69%	8.25%	-28.54%
Income Tax
% Of Pretax Income
Net Earnings	-$1.562M	-$3.695M	-$3.413M
YoY Change	-57.69%	8.25%	-28.54%
Net Earnings / Revenue	-47.81%	-115.39%	-112.98%
Basic Earnings Per Share	-$0.07	-$0.49	-$0.07
Diluted Earnings Per Share	-$0.07	-$0.49	-$0.07
COMMON SHARES
Basic Shares Outstanding	22.45M shares	21.48M shares	51.05M shares
Diluted Shares Outstanding	22.49M shares	14.17M shares	52.51M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments			$51.43K
YoY Change			-99.29%
Cash & Equivalents	$173.3K	$100.7K	$51.43K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$1.818M	$1.913M	$2.216M
Prepaid Expenses
Receivables	$1.500M	$1.518M	$1.513M
Other Receivables			$620.9K
Total Short-Term Assets	$4.064M	$4.094M	$4.401M
YoY Change	-21.51%	-6.97%	-59.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.58K	$14.06K	$20.02K
YoY Change	-32.13%	-29.74%	-22.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.228M	$1.327M	$1.743M
YoY Change	-25.4%	-23.91%	33.79%
TOTAL ASSETS
Total Short-Term Assets	$4.064M	$4.094M	$4.401M
Total Long-Term Assets	$1.228M	$1.327M	$1.743M
Total Assets	$5.292M	$5.421M	$6.144M
YoY Change	-22.45%	-11.77%	-49.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$4.174M
YoY Change			186.27%
Accrued Expenses	$4.233M	$3.199M	$2.390M
YoY Change	99.7%	33.89%	92.21%
Deferred Revenue
YoY Change
Short-Term Debt			$5.600M
YoY Change			352.35%
Long-Term Debt Due			$600.0K
YoY Change
Total Short-Term Liabilities	$21.49M	$20.58M	$15.10M
YoY Change	20.56%	36.31%	229.82%
LONG-TERM LIABILITIES
Long-Term Debt			$12.50M
YoY Change			-0.26%
Other Long-Term Liabilities			$1.958M
YoY Change			22.42%
Total Long-Term Liabilities			$14.46M
YoY Change			2.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.49M	$20.58M	$15.10M
Total Long-Term Liabilities			$14.46M
Total Liabilities	$34.17M	$33.01M	$29.56M
YoY Change	5.81%	11.7%	57.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$136.1M	-$134.4M	-$116.2M
YoY Change	13.32%	15.73%	18.47%
Common Stock	$23.02K	$21.65K	$52.51K
YoY Change	161.31%	-58.78%	1.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$31.17M	-$29.78M	-$23.41M
YoY Change
Total Liabilities & Shareholders Equity	$5.292M	$5.421M	$6.144M
YoY Change	-22.45%	-11.77%	-49.43%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.562M	-$3.695M	-$3.413M
YoY Change	-57.69%	8.25%	-28.54%
Depreciation, Depletion And Amortization		$1.488K	$1.489K
YoY Change		-0.07%	0.0%
Cash From Operating Activities		-$1.494M	-$1.832M
YoY Change		-18.44%	-54.64%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$868.2K	$1.329M
YoY Change		-34.68%	-259.52%
NET CHANGE
Cash From Operating Activities		-$1.494M	-$1.832M
Cash From Investing Activities
Cash From Financing Activities		$868.2K	$1.329M
Net Change In Cash		-$626.1K	-$503.0K
YoY Change		24.47%	-89.65%
FREE CASH FLOW
Cash From Operating Activities		-$1.494M	-$1.832M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	BTCY	Deemed Dividends DeemedDividends		usd
CY2024Q2	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues		usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2024Q2	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices		usd
CY2023Q2	BTCY	Issuance Of Warrants For Services IssuanceOfWarrantsForServices		usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2024Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2024Q2	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases		usd
CY2023Q2	BTCY	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issue FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue		usd
CY2023Q2	BTCY	Reduction Due To Preferred Shares Converted ReductionDueToPreferredSharesConverted		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2024Q2	BTCY	Operating Lease Right Of Use Asset New Leases OperatingLeaseRightOfUseAssetNewLeases		usd
CY2023Q2	BTCY	Operating Lease Right Of Use Asset New Leases OperatingLeaseRightOfUseAssetNewLeases		usd
CY2024Q2	BTCY	Operating Lease New Leases OperatingLeaseNewLeases		usd
CY2023Q2	BTCY	Operating Lease New Leases OperatingLeaseNewLeases		usd
CY2024Q2	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions		usd
CY2024Q2	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals		usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1		usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	838575	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1104061	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	2363168	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	1916704	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2966119	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3520215	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	513895	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	712975	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	3480014	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	4233190	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1116846	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2316486	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	768673	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	660512	usd
CY2024Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1144728	usd
CY2023Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-557219	usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-306862	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	101452	usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-127611	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	6448	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-229800	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13435	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3694520	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3412882	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3694520	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3412882	usd
CY2024Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	199092	usd
CY2023Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	188697	usd
CY2024Q2	BTCY	Deemed Dividends DeemedDividends	-3054680	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6948292	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3601579	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	23583	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-175830	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6924709	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3777409	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.490
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.490
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.411
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.411
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14169441	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14169441	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8752510	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8752510	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-31465737	usd
CY2024Q2	BTCY	Issuance Of Common Shares From At The Market Transaction Value IssuanceOfCommonSharesFromAtTheMarketTransactionValue	125227	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	231722	usd
CY2024Q2	BTCY	Stock Issued During Period Value Conversion Of Convertible Securities One StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne	4934702	usd
CY2024Q2	BTCY	Stock Issued During Period Value Conversion Of Convertible Securities Two StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesTwo	2208599	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	61120	usd
CY2024Q2	BTCY	Stock Issued During Period Value For Settlement Of Accounts Payable StockIssuedDuringPeriodValueForSettlementOfAccountsPayable	990408	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	58978	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	23583	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3694520	usd
CY2024Q2	BTCY	Preferred Stock Dividends PreferredStockDividends	199092	usd
CY2024Q2	BTCY	Accumulated Deficit Deemed Dividend AccumulatedDeficitDeemedDividend	-3054680	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-29779690	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-19845385	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-19845385	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	211180	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-175830	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3412882	usd
CY2023Q2	BTCY	Preferred Stock Dividends PreferredStockDividends	188697	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-23411614	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-23411614	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3694520	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3412882	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	58978	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	211180	usd
CY2024Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	61120	usd
CY2024Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1144728	usd
CY2023Q2	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-557219	usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-306862	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	101452	usd
CY2024Q2	BTCY	Gain Loss Upon Convertible Promissory Notes Conversion And Redemption GainLossUponConvertiblePromissoryNotesConversionAndRedemption	376704	usd
CY2023Q2	BTCY	Gain Loss Upon Convertible Promissory Notes Conversion And Redemption GainLossUponConvertiblePromissoryNotesConversionAndRedemption	-6448	usd
CY2024Q2	us-gaap	Depreciation Depreciation	1488	usd
CY2023Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2024Q2	BTCY	Noncash Lease Expenses NoncashLeaseExpenses	97577	usd
CY2023Q2	BTCY	Noncash Lease Expenses NoncashLeaseExpenses	87801	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2819	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	331009	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	33888	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-121446	usd
CY2024Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	225789	usd
CY2023Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	32333	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	415319	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1072871	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1494240	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1832118	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	125221	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1312532	usd
CY2024Q2	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	280000	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	855538	usd
CY2024Q2	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-837606	usd
CY2023Q2	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	479656	usd
CY2024Q2	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	11967	usd
CY2023Q2	BTCY	Repayments Of Preferred Stock Dividend RepaymentsOfPreferredStockDividend	6049	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	868180	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1329145	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-626060	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-502973	usd
CY2024Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-59269	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-16054	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	786060	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	570460	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	100731	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51433	usd
CY2024Q2	us-gaap	Interest Paid Net InterestPaidNet	707412	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	258689	usd
CY2024Q2	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zDgBo9HBwZZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_822_zN3MyvyL4A68">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company” or “Biotricity”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over on February 2, 2016.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company (directly and through its subsidiary) is engaged in research and development activities within the remote monitoring segment of preventative care. It is focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted to building and commercializing an ecosystem of technologies that enable access to this market.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-134448077	usd
CY2024Q2	BTCY	Working Capital Deficiency WorkingCapitalDeficiency	-16485643	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1476121	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2355318	usd
CY2024	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	853030	usd
CY2024	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2962386	usd
CY2024	BTCY	Stock Issued During Period Share Conversion Of Convertible Securities StockIssuedDuringPeriodShareConversionOfConvertibleSecurities	36897	shares
CY2024	BTCY	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	123347	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	119285	usd
CY2024	BTCY	Placement Fee Percentage PlacementFeePercentage	0.03	pure
CY2024Q2	BTCY	Stock Issued During Period Share Conversion Of Convertible Securities StockIssuedDuringPeriodShareConversionOfConvertibleSecurities	97811	shares
CY2024Q2	BTCY	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	125227	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3201743	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3020765	usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1099433	usd
CY2024Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1128700	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	813857	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	750702	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1913290	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1879402	usd
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_z7lyywpePK0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zSCslrDcQvLb">Significant accounting estimates and assumptions</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed consolidated financial statements requires the use of estimates and assumptions to be made in applying the accounting policies that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. The estimates and related assumptions are based on previous experiences and other factors considered reasonable under the circumstances, the results of which form the basis for making the assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant accounts that require estimates as the basis for determining the stated amounts include share-based compensation, impairment analysis and fair value of warrants, promissory notes, convertible notes and derivative liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of stock options</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of equity instruments at the date at which they are granted. Estimating fair value for share-based payments requires determining the most appropriate valuation model for a grant of such instruments, which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate inputs to the Black-Scholes option pricing model, including the expected life of the instrument, risk-free rate, volatility, and dividend yield.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of warrants</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair value of the warrant issued for services and issue pursuant to financing transactions, the Company used the Black-Scholes option pricing model with the following assumptions: volatility rate, risk-free rate, and the remaining expected life of the warrants that are classified under equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair value of derivative liabilities</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used Monte-Carlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Functional currency</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determining the appropriate functional currencies for entities in the Company requires analysis of various factors, including the currencies and country-specific factors that mainly influence labor, materials, and other operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Useful life of property and equipment</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company employs significant estimates to determine the estimated useful lives of property and equipment, considering industry trends such as technological advancements, past experience, expected use and review of asset useful lives. The Company makes estimates when determining depreciation methods, depreciation rates and asset useful lives, which requires considering industry trends and company-specific factors. The Company reviews depreciation methods, useful lives and residual values annually or when circumstances change and adjusts its depreciation methods and assumptions prospectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIOTRICITY INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUNE 30, 2024 (Unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in US dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Provisions</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions are recognized when the Company has a present obligation, legal or constructive, as a result of a previous event, if it is probable that the Company will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Contingencies</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingencies can be either possible assets or possible liabilities arising from past events, which, by their nature, will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential impact of contingencies inherently involves the exercise of significant judgment and the use of estimates regarding the outcome of future events.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Inventory obsolescence</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost and market value. Market value of our inventory, which is all purchased finished goods, is determined based on its estimated net realizable value, which is generally the selling price less normally predictable costs of disposal and transportation. The Company estimates net realizable value as the amount at which inventories are expected to be sold, taking into consideration fluctuations in retail prices less estimated costs necessary to make the sale. Inventories are written down to net realizable value when the cost of inventories is estimated to be unrecoverable due to obsolescence, damage, or declining selling prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income and other taxes</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of current and deferred income taxes requires the Company to make estimates and assumptions and to exercise judgment regarding the carrying values of assets and liabilities which are subject to accounting estimates inherent in those balances, the interpretation of income tax legislation across various jurisdictions, expectations about future operating results, the timing of reversal of temporary differences and possible audits of income tax filings by the tax authorities. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Changes or differences in underlying estimates or assumptions may result in changes to the current or deferred income tax balances on the consolidated balance sheets, a charge or credit to income tax expense included as part of net income (loss) and may result in cash payments or receipts. Judgment includes consideration of the Company’s future cash requirements in its tax jurisdictions. All income, capital and commodity tax filings are subject to audits and reassessments. Changes in interpretations or judgments may result in a change in the Company’s income, capital, or commodity tax provisions in the future. The amount of such a change cannot be reasonably estimated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Incremental borrowing rate for lease</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The determination of the Company’s lease obligation and right-of-use asset depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company’s incremental borrowing rate. Significant assumptions are required to be made when determining which borrowing rates to apply in this determination. Changes in the assumptions used may have a significant effect on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIOTRICITY INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JUNE 30, 2024 (Unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Expressed in US dollars)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	100731	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	100731	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	516107	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1323374	usd
CY2024Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1839481	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	786060	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	786060	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	991866	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1435668	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2427534	usd
CY2024Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4811090	usd
CY2024Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	5081992	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3199402	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4369576	usd
CY2024Q2	us-gaap	Deferred Revenue DeferredRevenue	79013	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	21550	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8089505	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9473118	usd
CY2024Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	246058	usd
CY2024Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	837945	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	15836	usd
CY2023	us-gaap	Debt Conversion Description DebtConversionDescription	The redemption price was determined in accordance to the Series B note agreement, where the Company has an option to redeem the note at 115% of its principal value instead of converting the note upon receipt of a conversion notice. The difference between the redemption cash payment and the book value of the note redeemed, including the derivative liability associated to the note
CY2024	BTCY	Finance Charges FinanceCharges	50000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Revolving Credit Conversion To Term Loan Description LineOfCreditFacilityRevolvingCreditConversionToTermLoanDescription	In assigning the selling accounts receivables to the revolving loan lender, the Company is receiving 85% of their value as an advance of its regular collection of those receivables, limited to $1.2 million in financing, and expects to receive the remaining balance as part of normal collection activities.
CY2023Q2	us-gaap	Financing Receivable Revolving Converted To Term Loan FinancingReceivableRevolvingConvertedToTermLoan	1200000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	300000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	1398111	usd
CY2024	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	1286792	usd
CY2024Q1	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	125000	usd
CY2024Q2	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	1411792	usd
	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	1411792	usd
CY2024Q2	us-gaap	Interest Expense Other InterestExpenseOther	105233	usd
CY2023Q2	us-gaap	Interest Expense Other InterestExpenseOther	45217	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12400000	usd
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2026-12-21
CY2021Q4	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.105	pure
CY2021Q4	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2022-02-15
CY2021Q4	us-gaap	Debt Instrument Payment Terms DebtInstrumentPaymentTerms	Pursuant to the Credit Agreement, the Company will be required to make interest only payments for the first 24 months (which may be extended to 36 months under prescribed circumstances), after which payments will include principal amortization that accommodates a 40% balloon principal payment at maturity. The Company and the Lender have negotiated the terms under which the Company will be allowed to extend the interest-only period and delay the start of principal repayment.
CY2024	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	2400000	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	600000	usd
CY2023Q3	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	600000	usd
CY2023Q4	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	600000	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	600000	usd
CY2024Q2	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	600000	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	3000000	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	2400000	usd
CY2021Q4	BTCY	Origination Fee Amount OriginationFeeAmount	120000	usd
CY2021Q4	BTCY	Exit Fees ExitFees	600000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	193437	usd
CY2021Q4	us-gaap	Professional Fees ProfessionalFees	48484	usd
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	144953	usd
CY2021Q4	us-gaap	Proceeds From Loans ProceedsFromLoans	12000000	usd
CY2021Q4	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1574068	usd
CY2021Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1042149	usd
CY2024Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	51831	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	50942	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	364000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	972008	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	795656	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	57536	shares
CY2021Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	198713	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1435668	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	759065	usd
CY2024Q2	BTCY	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issue FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssue	472341	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	300438	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-79827	usd
CY2024Q2	BTCY	Reduction Due To Preferred Shares Converted ReductionDueToPreferredSharesConverted	-885073	usd
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1323374	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	679238	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	160672	shares
CY2024Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	160672	shares
CY2024Q2	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.10	pure
CY2024Q1	BTCY	Convertible Preferred Stock ConvertiblePreferredStock	1488920	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1312532	usd
CY2024Q2	BTCY	Change In Fair Valueus Measurement With Reconciliation Recurring Basis Liability ChangeInFairValueusMeasurementWithReconciliationRecurringBasisLiability	-472341	usd
CY2024Q2	BTCY	Conversion Into Common Shares ConversionIntoCommonShares	-142908	usd
CY2024Q2	BTCY	Convertible Preferred Stock ConvertiblePreferredStock	2186203	usd
CY2024Q2	BTCY	Loss On Debt Conversion LossOnDebtConversion	249093	usd
CY2024Q2	BTCY	Stock Issued During Period Share Conversion Of Convertible Securities StockIssuedDuringPeriodShareConversionOfConvertibleSecurities	97811	shares
CY2024Q2	BTCY	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	125227	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1331019	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1331019	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1331019	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1331019	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.48
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.47
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0433	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0385	pure
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.171	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.384
CY2024Q2	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0	pure
CY2023Q2	BTCY	Expected Forfeiture Attrition Rates ExpectedForfeitureAttritionRates	0.0000	pure
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114	pure
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1221593	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1587492	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	97577	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	87801	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1124016	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1499691	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1386486	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1722095	usd
CY2024Q2	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	108080	usd
CY2023Q2	BTCY	Operating Lease Repayment And Interest Accretion OperatingLeaseRepaymentAndInterestAccretion	94074	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1278406	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1628021	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	475026	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	457371	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	803380	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	929115	usd
CY2024Q2	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	145338	usd
CY2023Q2	us-gaap	Proceeds From Lease Payments ProceedsFromLeasePayments	141105	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	552293	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	600288	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	565359	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1717940	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	439534	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1278406	usd
CY2022Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	12928	usd
CY2022Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	16839	usd
CY2024Q2	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	0	usd
CY2023Q2	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	0	usd
CY2024Q2	us-gaap	Depreciation Depreciation	1488	usd
CY2023Q2	us-gaap	Depreciation Depreciation	1489	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29767	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14215	usd
CY2024Q2	us-gaap	Depreciation Depreciation	1488	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15703	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15552	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14064	usd

Files In Submission

Name	View Source	Status
0001493152-24-033159-index-headers.html	Edgar Link	pending
0001493152-24-033159-index.html	Edgar Link	pending
0001493152-24-033159.txt	Edgar Link	pending
0001493152-24-033159-xbrl.zip	Edgar Link	pending
btcy-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
btcy-20240630_cal.xml	Edgar Link	unprocessable
btcy-20240630_def.xml	Edgar Link	unprocessable
btcy-20240630_lab.xml	Edgar Link	unprocessable
btcy-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTCY
BIOTRICITY INC. Stock $btcy

2024 Q3 Form 10-Q Financial Statement

#000149315224033159 Filed on August 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY BIOTRICITY INC. Stock $btcy

2024 Q3 Form 10-Q Financial Statement

#000149315224033159 Filed on August 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCY
BIOTRICITY INC. Stock $btcy